APA (7th ed.) Citation

N, P., A, C., C, C., P, Z., M, M., MC, T., . . . L, A. (2026). Occult hepatitis B virus infection status is not associated with impaired efficacy of anti-CD19 CAR-T-cell therapy for lymphoma and shows a distinct immune toxicity profile: Results from the CART-SIE study. HemaSphere, 10(5), e70362. https://doi.org/10.1002/hem3.70362

Chicago Style (17th ed.) Citation

N, Polverelli, et al. "Occult Hepatitis B Virus Infection Status Is Not Associated with Impaired Efficacy of Anti-CD19 CAR-T-cell Therapy for Lymphoma and Shows a Distinct Immune Toxicity Profile: Results from the CART-SIE Study." HemaSphere 10, no. 5 (2026): e70362. https://doi.org/10.1002/hem3.70362.

MLA (9th ed.) Citation

N, Polverelli, et al. "Occult Hepatitis B Virus Infection Status Is Not Associated with Impaired Efficacy of Anti-CD19 CAR-T-cell Therapy for Lymphoma and Shows a Distinct Immune Toxicity Profile: Results from the CART-SIE Study." HemaSphere, vol. 10, no. 5, 2026, p. e70362, https://doi.org/10.1002/hem3.70362.